Bristol Myers Squibb in Austria

Transforming patients' lives through science™





Our mission

To discover, develop and deliver innovative medicines that help patients prevail over serious diseases.





Our vision

To be the world's leading biopharma company that transforms patients' lives through science.





Our values

INTEGRITY

We demonstrate ethics, integrity and quality in everything we do for patients, customers and colleagues

INNOVATION

We pursue disruptive and bold solutions for patients

URGENCY

We move together with speed and quality because patients are waiting

PASSION

Our dedication to learning and excellence helps us to deliver exceptional results


ACCOUNTABILITY

We all own BMS' success and strive to be transparent and deliver on our commitments

INCLUSION

We embrace diversity and foster an environment where we can all work together at our full potential

Our Global Presence



Bristol Myers Squibb in Austria

>110

Employees work for BMS in Austria one of the 50 BMS locations worldwide.



Our ambition is to be **one of the best** employers in Austria. Ranking 1st in the "Great Place To Work" survey proves that we are taking this seriously.


> Best Workplaces™ 1st Place Great Place To Work。AUSTRIA 2020



Collaboration and Partnerships



We drive collaborative and constructive partnerships and open dialogue among stakeholders to create a healthcare system that provides patients with innovative medicines in a sustainable way.



Research and Development

Through our leading role in the conduct of clinical studies in Austria, we contribute significantly to strengthening and maintaining Austria as a research location. We believe in the power of science, to fight cancer and other diseases that belong to the most challenging diseases of our time.

Clinical studies together with University Hospitals and other hospital across Austria in 2019.

Investigational therapies globally in the areas of:

Oncology, Hematology, Cardiovascular, Immunology, Fibrotic Diseases, Neuroscience



50+

Our Pipeline

We have one of the most diverse and promising pipelines in the industry fueled by research in **oncology**, **hematology**, **immunology**, and **cardiovascular diseases**.

Leading Franchises	Deep and Broad Late-Stage Pipeline	Robust Early-Stage Pipeline Phase I/II Assets
# 1 Oncology & Hematology	<mark>8</mark> Near-term potential launches	19 Oncology
#1 Cardiovascular	9 Phase III assets	15 Hematology 5 Cardiovasulcar
Growing Immunology Franchise	20+ Life cycle management opportunities in IO	9 Immunology 5 Fibrosis

We come to work each day driven by our mission, acting with a sense of urgency for our patients and their families, because there is still so much more to do.

> - Giovanni Caforio, M.D., Chairman of the Board and Chief Executive Officer

Bristol Myers Squibb